DRUGS IN R&D is a premier open access journal dedicated to advancing the field of pharmacology and drug development. Published by Springer International Publishing AG, this journal has been a valuable resource for researchers and professionals since its inception in 1999, contributing critical insights into the pharmacological sciences. With an impressive Impact Factor reflecting its significance, DRUGS IN R&D ranks in the Q2 quartile for Pharmacology, according to 2023 metrics, and ranks #151 out of 313 in the field of pharmacology and toxicology on Scopus. This journal offers an open access format, ensuring high visibility and accessibility of research findings to a global audience, supporting the intrepid pursuit of knowledge in drug research and development. By facilitating comprehensive discussions and innovative research findings, DRUGS IN R&D plays a crucial role in shaping the future landscape of pharmacological studies and advancements.

GENE THERAPY, published by SpringerNature, is a prestigious academic journal at the forefront of research in the fields of genetics, molecular biology, and molecular medicine. Since its inception in 1994, this journal has evolved into a vital resource for scholars, practitioners, and students, providing cutting-edge insights into gene therapy techniques and innovations. With an impressive impact factor reflecting its significant influence— ranking in the Q1 quartile across multiple categories in 2023—GENE THERAPY offers rigorous peer-reviewed articles that address both basic and applied aspects of gene therapy. The journal is recognized for its role in promoting advancements in therapeutic strategies, thus enhancing understanding of genetic disorders and treatment efficacy. Researchers will find this journal invaluable for publishing their findings, staying updated on the latest breakthroughs, and fostering interdisciplinary collaborations. Engage with the latest in gene therapy by accessing this influential platform, and contribute to a field that holds the potential to transform healthcare outcomes worldwide.

ImmunoTargets and Therapy is a leading open access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the field of immunology and its various therapeutic applications. Since its inception in 2012, the journal has rapidly become a vital resource for researchers, professionals, and students, achieving notable recognition with a Q1 ranking in both Immunology and Immunology and Allergy categories as of 2023. With an impressive Scopus ranking of #22 out of 233 in Medicine - Immunology and Allergy, and #25 out of 236 in Immunology and Microbiology, this journal maintains a 90th percentile standing in its field. ImmunoTargets and Therapy not only publishes original research articles, reviews, and clinical studies, but also fosters an inclusive platform for the dissemination of innovative findings critical to the fight against immunological disorders. Based in New Zealand, it serves a global audience, promoting knowledge exchange and collaboration through its open access model.

Clinical Pharmacology-Advances and Applications is a premier open access journal published by DOVE MEDICAL PRESS LTD, based in New Zealand. Since its establishment in 2009, the journal has been dedicated to advancing the field of pharmacology by disseminating innovative research and applications related to medication therapy and patient outcomes. With its notable impact factor and current ranking within the top percentile of pharmacology journals, it provides an invaluable platform for researchers, healthcare professionals, and students to share knowledge and foster collaboration. The journal's content spans a wide range of topics, ensuring coverage of both fundamental and emerging areas in medical pharmacology. As of 2023, it holds a strong position in the Q2 quartile, underscoring its relevance and influence within the scientific community. Authors and readers alike benefit from its open access model, which ensures that critical findings are widely accessible, thereby enhancing the pace of discovery and application in clinical settings.

CLINICAL DRUG INVESTIGATION is a prestigious journal dedicated to the fields of Medicine and Pharmacology, published by ADIS INT LTD in the United Kingdom. With an ISSN of 1173-2563 and an E-ISSN of 1179-1918, this journal has been a crucial contributor to the scientific community since its inception in 1995. Recognized for its significant impact, it holds a commendable Q2 ranking in both the Medicine (miscellaneous) and Pharmacology (medical) categories, placing it firmly in the 70th percentile within its field. Researchers, professionals, and students alike benefit from its commitment to publishing innovative studies and comprehensive reviews that advance understanding and application of clinical drugs. Although it does not currently offer open access options, its rigorous peer-review process ensures the integrity and quality of published articles. The journal's scope encompasses a wide range of topics related to drug investigation, making it an essential resource for anyone involved in medical research and pharmacological practice.

CURRENT MEDICAL RESEARCH AND OPINION, published by Taylor & Francis Ltd, is a distinguished journal that has been at the forefront of medical research since its inception in 1972. With a vested interest in advancing healthcare knowledge, this journal encompasses a wide array of disciplines within the medical field, categorizing itself in Q2 of the Medicine (Miscellaneous) category according to the 2023 rankings. Notably, it holds a commendable rank of #119 out of 636 in the General Medicine category on Scopus, indicating its relevance and influence within the medical community, supported by an 81st percentile ranking. Although it does not present Open Access options, the comprehensive research articles, systematic reviews, and expert opinions it publishes are crucial for researchers, clinicians, and students who seek to deepen their understanding and drive innovations in medical practice. With its commitment to high-quality and impactful scientific communication, CURRENT MEDICAL RESEARCH AND OPINION remains an essential resource for those dedicated to advancing healthcare and improving patient outcomes.

The Journal of Dietary Supplements, published by TAYLOR & FRANCIS LTD, stands as a premier academic outlet in the fields of food science, nutrition, and pharmacology. With a notable impact factor reflecting its rigorous peer-review process and high-quality research, this journal serves as an essential resource for researchers, healthcare professionals, and students alike. Its indexed ISSN 1939-0211 and E-ISSN 1939-022X signify its dedication to disseminating cutting-edge studies and reviews, covering topics from dietary interventions to the efficacy of various supplements. Since its inception in 2008, the journal has emerged as a vital contributor to the scientific community, maintaining a Q2 rank in multiple categories, indicating its influence and reach. While it operates under a traditional subscription model, the journal’s commitment to advancing knowledge in nutrition and dietary science is evident in its comprehensive scope and a diverse array of high-impact articles. Located in the United States, the journal continues to invite submissions that will advance understanding and application of dietary supplements in enhancing health outcomes.

Kidney Cancer, published by IOS PRESS, is an esteemed open-access journal dedicated to advancing knowledge in the field of nephrology and oncology. Since its inception in 2017, this journal has provided a dynamic platform for researchers, practitioners, and students to disseminate their findings and discuss innovative approaches to kidney cancer treatment and research. With an ongoing commitment to fostering collaboration and sharing critical insights, Kidney Cancer aims to bridge gaps in understanding and promote new methodologies in patient care. Despite its current ranking in the lower quartiles of its category, the journal is positioned to make significant contributions to the academic community by publishing high-quality, peer-reviewed articles that enhance the discourse in kidney cancer research. Furthermore, its open-access model ensures that valuable research is accessible to a global audience, supporting the urgent need for advancements in this critical area of health. Join the conversation and contribute to the growing body of knowledge in this vital field.

Translational and Clinical Pharmacology, published by KSCPT, is an esteemed journal that serves as a vital source of knowledge in the field of pharmacology, particularly focusing on the translational aspects that bridge laboratory research and clinical applications. Established in 2014, this journal aims to disseminate high-quality research and reviews pertaining to drug development, therapeutics, and the underlying mechanisms of action in the medical realm. With an ISSN of 2289-0882 and an E-ISSN of 2383-5427, it holds a significant position with a Q3 ranking in the pharmacology category as of 2023, emphasizing its role in advancing scientific understanding within this crucial discipline. While it operates as a traditional subscription-based journal, its output remains accessible through various academic platforms, contributing to the global discourse in pharmacology. Researchers, professionals, and students will find value in its insightful articles and comprehensive studies, underscoring the journal’s commitment to enhancing pharmacological knowledge and practice.

Welcome to the Journal of Clinical Pharmacology, an esteemed publication in the field of pharmacology and medical pharmacology, published by Wiley. Since its inception in 1973, this journal has been at the forefront of disseminating innovative research findings and comprehensive reviews that enhance our understanding of drug therapies and their clinical applications. With an impact factor that reflects its strong reputation and a Scopus ranking placing it in the 64th percentile among 272 journals in medical pharmacology, the journal stands as a critical resource for researchers, healthcare professionals, and students alike. Although currently not an Open Access journal, it provides invaluable insights into therapeutic drug use and safety, the pharmacokinetics of drugs, and the development of new therapeutic strategies. The journal's commitment to advancing the field through high-quality, peer-reviewed articles ensures it remains a vital asset in the continuously evolving landscape of clinical pharmacology.